Who Prioritizes Innovation? R&D Spending Compared for Dynavax Technologies Corporation and Celldex Therapeutics, Inc.

Biotech R&D: Celldex vs. Dynavax Spending Trends

__timestampCelldex Therapeutics, Inc.Dynavax Technologies Corporation
Wednesday, January 1, 201410438100084580000
Thursday, January 1, 201510017100086943000
Friday, January 1, 201610272600084493000
Sunday, January 1, 20179617100064988000
Monday, January 1, 20186644900074951000
Tuesday, January 1, 20194267200062331000
Wednesday, January 1, 20204253400028607000
Friday, January 1, 20215331100032228000
Saturday, January 1, 20228225800046600000
Sunday, January 1, 202311801100054886000
Loading chart...

Unleashing the power of data

Innovation in Biotech: A Comparative Analysis

In the ever-evolving world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Celldex Therapeutics, Inc. and Dynavax Technologies Corporation have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Celldex consistently outspent Dynavax, with an average annual R&D expenditure of approximately 30% more. Notably, in 2023, Celldex's R&D spending surged to its highest, marking a 40% increase from its 2020 low. Meanwhile, Dynavax's R&D investment peaked in 2015 but has since seen a gradual decline, dropping by nearly 35% by 2023. This trend highlights Celldex's aggressive pursuit of innovation, while Dynavax appears to be adopting a more conservative approach. As the biotech landscape continues to shift, these spending patterns may offer insights into each company's strategic priorities and future growth potential.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025